KAMADA LTD
Business
Kamada Ltd is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions. The company markets six FDA-approved plasma-derived products (KEDRAB, GLASSIA, CYTOGAM, WINRHO SDF, VARIZIG, HEPAGAM B) plus KAMRAB and equine-based anti-snake venom products, with distribution across 30+ countries. Kamada operates two reportable segments: Proprietary Products (specialty plasma therapies and normal source plasma sales) and Distribution (in-licensed third-party biopharmaceutical products distributed in Israel and expanding to the MENA region).
Summary from 20-F filed 2026-03-11
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $20.20M |
| Total assets | $378.71M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is KAMADA LTD's CIK number?
KAMADA LTD's SEC CIK number is 0001567529 (1567529). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find KAMADA LTD's SEC filings?
All of KAMADA LTD's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.